Treatment of pancreatic cancer with intravenous vitamin C
Authors:
Open Access
- 1 April 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 29 (4) , 373-379
Abstract
Pancreatic ductal adenocarcinoma (PDA) has a dismal prognosis and is often discovered at an advanced stage with few therapeutic options. Current conventional regimens for PDA are associated with significant morbidity, decreased quality of life, and a considerable financial burden. As a result, some patients turn to integrative medicine therapies as an alternate option after a diagnosis of PDA. Intravenous pharmacologic ascorbic acid (PAA) is one such treatment. The use of PAA has been passionately debated for many years, but more recent rigorous scientific research has shown that there are significant blood concentration differences when ascorbic acid is given parenterally when compared to oral dosing. This pharmacologic difference appears to be critical for its role in oncology. Here, we report the use of PAA in a patient with poorly differentiated stage IV PDA as an exclusive chemotherapeutic regimen. The patient survived nearly 4 years after diagnosis, with PAA as his sole treatment, and he achieved objective regression of his disease. He died from sepsis and organ failure from a bowel perforation event. This case illustrates the possibility of PAA to effectively control tumor progression and serve as an adjunct to standard of care PDA chemotherapy regimens. Our patient’s experience with PAA should be taken into consideration, along with previous research in cell, animal, and clinical experiments to design future treatment trials.Keywords
This publication has 22 references indexed in Scilit:
- Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic CancerPLOS ONE, 2012
- Endo-Biliary Stents for Benign Disease: Not Always Benign after All!Clinics and Practice, 2011
- Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancerFree Radical Biology and Medicine, 2011
- Vitamin C: A Concentration-Function Approach Yields Pharmacology and Therapeutic DiscoveriesAdvances in Nutrition, 2011
- Vitamin C: Intravenous Use by Complementary and Alternative Medicine Practitioners and Adverse EffectsPLOS ONE, 2010
- Losing and finding a way at C: New promise for pharmacologic ascorbate in cancer treatmentFree Radical Biology and Medicine, 2009
- Colonic Perforation by a Percutaneously Displaced Biliary Stent: Report of a Case and a Review of Current PracticeJournal of Vascular and Interventional Radiology, 2009
- Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in miceProceedings of the National Academy of Sciences, 2008
- Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivoProceedings of the National Academy of Sciences, 2007
- Failure of High-Dose Vitamin C (Ascorbic Acid) Therapy to Benefit Patients with Advanced CancerNew England Journal of Medicine, 1979